



February 2018 Newsletter

Volume 6 Issue 2

A Letter from the Founder, Dr. Christine Brezden-Masley

Dear CCTC Members,

It has been over 6 years since the CCTC was launched in October 2011. Thank you for your continued support of the website and use of the e-referral clinical trial portal. Our next phase is to develop an 'app' so the CCTC can be more accessible at your fingertips. Watch out for this in mid-2018.

We welcome and encourage suggestions so we can continue to improve the service of the CCTC. Simply please send us an email. Our goal is to showcase as many oncology clinical trials that are open in Ontario, providing ready access for your patients.

Sincerely,

Dr. Christine Brezden-Masley
Founder, CCTC

A Letter from the Project Manager, Alexandra Moskalewicz

Hello everyone,

Feel free to share this newsletter with any cancer care colleagues that may be interested, as we are always happy to have new members join our network!

Our 'Trials of the Month', featured on page 2 of this newsletter and on our website, is a great place to bring more emphasis to a trial that you or your institution would like to increase recruitment for. Please contact me any time at comettrials@smh.ca to nominate a trial!

Kind regards,

Alexandra Moskalewicz

ARTICLE RECOMMENDATION

Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands Van den Bogert C, Souverein P, Brekelmans C, Janssen S, Koëter G, Leufkens H, Bouter L
DOI: [10.1016/j.jclinepi.2017.05.001](https://doi.org/10.1016/j.jclinepi.2017.05.001) Published August 2017

Objective: To identify the reasons for discontinuation of clinical drug trials and to evaluate whether efficacy-related discontinuations were adequately planned in the trial protocol.

Study Design: All clinical drug trials in the Netherlands, reviewed by IRBs in 2007, were followed until December 2015. Reasons for trial discontinuation were the primary outcome of the study. Three reasons for discontinuation were analyzed separately: all cause, recruitment failure, and efficacy related (when an interim analysis had demonstrated futility or superiority). Among the efficacy-related discontinuations, we examined whether the data monitoring committee, the stopping rule, and the moment of the interim analysis in the trial progress were specified in the trial protocol.

Results: Of the 574 trials, 102 (17.8%) were discontinued. The most common reasons were recruitment failure (33 of 574; 5.7%) and solely efficacy related (30 of 574; 5.2%). Of the efficacy-related discontinuations, 10 of 30 (33.3%) of the trial protocols reported all three aspects in the trial protocol, and 20 of 30 (66.7%) reported at least one aspect in the trial protocol.

Conclusion: One out of five clinical drug trials is discontinued before the planned trial end, with recruitment failure and futility as the most common reasons. The target sample size of trials should be feasible, and interim analyses should be adequately described in trial protocols.

TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Skin	Total
Imaging Study	-	1	-	-	2	-	-	1	-	-	-	4
Observational	1	3	-	-	-	1	-	1	-	-	-	6
Prevention	-	-	-	1	-	-	-	1	-	-	-	2
Radiation	-	2	-	3	4	-	1	-	5	-	-	15
Supportive Care	1	5	-	-	-	-	-	-	-	-	-	6
Surgical Therapy	-	1	1	-	1	1	1	-	-	-	-	5
Systemic Therapy	1	9	-	15	21	4	2	11	11	5	4	83
Therapeutic	-	1	-	-	4	1	-	3	-	-	-	9
TOTAL	3	22	1	19	32	7	4	17	16	5	4	130



February 2018 Newsletter

Volume 6, Issue 2

TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	HER2CLIMB	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma	<ul style="list-style-type: none"> • HER2+ • Advanced breast cancer • Systemic Therapy 	Odette Cancer Centre Princess Margaret Cancer Centre
GU	IMbassador 250	A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen	<ul style="list-style-type: none"> • Metastatic Castration-Resistant Prostate Cancer (mCRPC) • 2nd line 	Odette Cancer Centre
Heme	C16021	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	<ul style="list-style-type: none"> • Multiple Myeloma • Newly Diagnosed • Systemic Therapy 	Royal Victoria Regional Health Centre
GYN	FORWARD 1	A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer	<ul style="list-style-type: none"> • Cancer of the Ovaries, Peritoneum, or Fallopian Tubes • Systemic Therapy 	London Health Sciences Centre
Lung	BR.34	A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With High-Risk Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	<ul style="list-style-type: none"> • Metastatic • Squamous or non-squamous, non-small cell carcinoma • Systemic Therapy 	Cambridge Memorial Hospital North York General Hospital
Mel	IND.224	A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	<ul style="list-style-type: none"> • Melanoma with brain metastases • BRAF V600 Mutation-Positive • Systemic Therapy 	Odette Cancer Centre
GI	AX-CSARC	A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer	<ul style="list-style-type: none"> • Biliary tract cancer • 1st line • Systemic Therapy 	Odette Cancer Centre



[Click here to NOMINATE your trial for Trials of the Month!](#)



MEMBERSHIP UPDATES

277 members

31 institutions

130 accruing trials



ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8

comettrials@smh.ca
(416) 809-3915

 [@COMET_Trials](https://twitter.com/COMET_Trials)
www.comettrials.com

INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	4
Grand River Hospital	Waterloo	9	1
Humber River Regional Hospital	Toronto	5	4
Kingston General Hospital	Kingston	4	22
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	21	-
London Health Sciences Centre	London	9	60
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	1
Mount Sinai Hospital	Toronto	2	3
North York General Hospital	Toronto	14	7
Odette Cancer Centre/Sunnybrook	Toronto	55	54
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	23	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	23	17
Scarborough General Hospital	Toronto	3	-
Southlake Regional Health Centre	Newmarket	19	8
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	15	4
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Toronto East General Hospital	Toronto	6	-
Trillium Health Partners	Mississauga	17	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	1	-
Wingham and District Hospital	Wingham	1	-